GlobeNewswire

GLOBAL INFRASTRUCTURE PARTNERS ANNOUNCES AGREEMENT TO ACQUIRE NRG ENERGY, INC.'S RENEWABLE ENERGY BUSINESS, INCLUDING:

Dela

THE CONTROLLING STAKE IN NRG YIELD AND RENEWABLES OPERATIONS & MAINTENANCE AND DEVELOPMENT BUSINESSES

 

New York, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Infrastructure Partners (GIP), a leading global, independent infrastructure investor, announced today that its third equity fund, Global Infrastructure Partners III, has agreed to acquire NRG Energy, Inc.'s (NYSE: NRG) integrated U.S. renewable energy platform, including its controlling stake and 46% economic interest in NRG Yield, Inc. (NYSE: NYLD; market capitalization: $3.2 billion) as well as NRG's renewable energy operations and maintenance ("O&M") and development businesses. GIP is acquiring the business for $1.375 billion in cash, subject to certain adjustments. In addition, GIP has agreed to provide backstop support for NYLD's agreed purchase of the Carlsbad Energy Center project.

 

NYLD has the largest project portfolio (by installed capacity) among U.S. power "yieldcos" and is the second largest by enterprise value and market capitalization. NYLD's operating power plant capacity totals 5.1 gigawatts ("GW", or thousands of megawatts "MW") and is diversified across wind, solar, and natural gas technologies. The company also owns thermal infrastructure assets with an aggregate steam and chilled water capacity of 1,319 net MWt and electric generation capacity of 123 net MW, servicing commercial businesses, universities, hospitals and government customers. A substantial portion of NYLD's project portfolio benefits from long-term contracts with a weighted average remaining contract life of 16 years.

 

In addition to NRG's interests in NYLD, GIP will acquire NRG's renewable O&M and development businesses. NRG's renewable O&M platform operates 2.4 GW of renewable power generation in 17 states. NRG's renewable development platform includes 630 MW of identified "dropdown" assets, which are subject to a right of first offer from NYLD, and it has a total project pipeline of over 6.4 GW of renewable generation opportunities across the U.S. (as last disclosed publicly by NRG).

 

GIP has a demonstrated track record of investment and value creation in the renewable energy sector, and this investment fits squarely into GIP's global renewables investment strategy. GIP has invested or committed approximately $9 billion of equity in the sector, including 8 GW of operating renewable assets and over 14 GW of renewable assets under construction or in development.

 

Adebayo Ogunlesi, Chairman and Managing Partner of GIP, said, "We are excited to announce the acquisition of NRG's world-class renewables business. We view each of the three acquired businesses - the NYLD stake, the O&M business, and the development business - as highly complementary and well positioned to capitalize on the increasing market demand for low cost, clean energy. We look forward to working with management to develop new renewable generation assets and to supporting the company with our deep operating and financial expertise in the sector. We are also excited about the opportunity to grow the value of NYLD, which allows public market investors to access attractive investments in renewable energy."

 

In addition to acquiring the business and assuming sponsorship of NYLD, GIP has made several significant commitments to facilitate the transaction, including arranging a $1.5 billion backstop credit facility to mitigate any change-of-control risk with NYLD's existing corporate debt and committing up to $400 million to backstop NYLD's acquisition of the 527 MW Carlsbad natural gas project in California from NRG. The commitment to the Carlsbad project, which remains subject to certain terms and conditions, ensures a timely acquisition in the event that NYLD is unable to raise efficient third-party capital to purchase the project.

 

Christopher Sotos, President and Chief Executive Officer of NYLD said, "Under NRG Energy's sponsorship, since its IPO in July 2013, NYLD has experienced tremendous success with an increase of 186% in cash available for distribution from $91 million to $260 million and an expansion of NYLD's quarterly dividend per share by 150% to $1.15 per share annualized at the end of 2017." Mr. Sotos continued, "With today's announcement, NYLD can look forward to its next phase of growth, including solidifying near-term objectives through the most recent drop down transactions and, most importantly, aligning with GIP, whose strategy and breadth of global investment capabilities are well suited to our business model and long-term objectives."

 

The Transaction is subject to customary closing conditions and is expected to close in the second half of 2018.

 

About NRG Yield

NRG Yield owns a diversified portfolio of contracted renewable and conventional generation and thermal infrastructure assets in the United States, including fossil fuel, solar and wind power generation facilities that have the capacity to support more than two million American homes and businesses. Its thermal infrastructure assets provide steam, hot and/or chilled water, and in some instances electricity, to commercial businesses, universities, hospitals and governmental units in multiple locations. NRG Yield's Class C and Class A common stock are traded on the New York Stock Exchange under the symbols NYLD and NYLD.A, respectively.

 

About Global Infrastructure Partners

Global Infrastructure Partners is an independent infrastructure fund that invests in infrastructure assets and businesses in both OECD and select emerging market countries. GIP targets investments in single assets and portfolios of assets and companies in power and utilities, natural resources infrastructure, air transport infrastructure, seaports, freight railroad, water distribution and treatment and waste management. GIP has offices in New York and London, with an affiliate in Sydney and portfolio company operations headquarters in Stamford, Connecticut. For more information, visit www.global-infra.com.

Jack Cowell
Global Infrastructure Partners
212 315 8133
Jack.Cowell@global-infra.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Global Infrastructure Partners via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum